These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32558721)

  • 1. 177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept.
    Kumar A; Ballal S; Yadav MP; ArunRaj ST; Haresh KP; Gupta S; Damle NA; Garg A; Tripathi M; Bal C
    Clin Nucl Med; 2020 Dec; 45(12):e512-e513. PubMed ID: 32558721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
    Vadi SK; Kumar R; Mittal BR; Parihar AS; Singh SK
    Clin Nucl Med; 2018 Apr; 43(4):276-278. PubMed ID: 29465493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprogression on 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT in a Treated Glioblastoma.
    Gupta M; Choudhury PS; Gairola M; Premsagar IC; Rao SA
    Clin Nucl Med; 2020 Aug; 45(8):621-622. PubMed ID: 32520501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of post-therapy
    Tuncel M; Telli T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?
    Kunikowska J; Kuliński R; Muylle K; Koziara H; Królicki L
    Clin Nucl Med; 2020 Jan; 45(1):11-18. PubMed ID: 31663868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
    Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
    Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Prospective Phase 2 Pilot Trial of
    Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
    Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
    Marafi F; Sasikumar A; Fathallah W; Esmail A
    Clin Nucl Med; 2020 Jan; 45(1):e61-e62. PubMed ID: 31162269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma.
    Sasikumar A; Joy A; Pillai MR; Nanabala R; Thomas B
    Clin Nucl Med; 2017 Feb; 42(2):e126-e127. PubMed ID: 27941377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Ballal S; Yadav MP; Raju S; Roesch F; Martin M; Tripathi M; Bal C
    Nucl Med Mol Imaging; 2024 Feb; 58(1):32-34. PubMed ID: 38261876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival.
    Acar E; Özdoğan Ö; Aksu A; Derebek E; Bekiş R; Çapa Kaya G
    Ann Nucl Med; 2019 Sep; 33(9):681-688. PubMed ID: 31214958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.